LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity
Free consultation with a DOZA specialist we'll select the optimal ALLUVI or SYNEDICA dose for your weight loss program Get a consultation Message on Telegram You May Also Be Interested In Mounjaro Dual GLP-1 + GIP agonist by Eli Lilly
We don't believe in one-size-fits-all solutions
Theyre not supplements or natural ingredients that claim to support GLP-1 theyre the real deal that directly affects your hormones and metabolism
Switching or combining these medicines should only be considered with qualified clinical oversight
Focus on nutrient-dense foods that support satiety and provide essential vitamins and minerals